AI Insight
Genespire and researchers at the San Raffaele Telethon Institute for Gene Therapy have published preclinical data on a liver-directed gene therapy for methylmalonic acidemia (MMA), a severe inherited metabolic disorder. The approach uses an immune-shielded lentiviral vector to deliver therapeutic genes to the liver. The preclinical results demonstrate potential efficacy for treating this condition.
Why it matters
Methylmalonic acidemia is a life-threatening metabolic disorder with limited treatment options. A successful gene therapy could provide a one-time treatment to address the underlying genetic cause rather than managing symptoms, potentially improving patient outcomes and quality of life.
Understand the Science
Genespire, in collaboration with researchers at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), announced the publication of preclinical data supporting the potential of its liver-directed immune-shielded lentiviral gene therapy approach to treat methylmalonic acidemia (MMA), a severe inherited metabolic disorder.
Source: Liver-directed gene therapy shows preclinical efficacy for severe inherited metabolic disorder